Therapeutics News and Research

RSS

SAGE Therapeutics doses first patient in SAGE-547 Phase 1/2 trial for treatment of SRSE

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening and rare central nervous system (CNS) disorders, today announced dose initiation of the first patient in a Phase 1/2 clinical trial of SAGE-547, a neuroactive steroid, in super-refractory status epilepticus (SRSE), a critical condition in which the brain is in a state of persistent seizure.

27 Mar 2014

Echo Therapeutics reports net loss of $3.9M in fourth quarter 2013

Echo Therapeutics, Inc., a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced financial results for the year ended December 31, 2013.

27 Mar 2014

Research may lead the way toward new treatments for proliferative retinopathies

A new report published online in The FASEB Journal may lead the way toward new treatments or a cure for a common cause of blindness (proliferative retinopathies). Specifically, scientists have discovered that the body's innate immune system does more than help ward off external pathogens.

27 Mar 2014

Mast Therapeutics reports net loss of $5.7 million for fourth quarter 2013

Mast Therapeutics, Inc. today reported financial results for the fourth quarter and year ended December 31, 2013.

26 Mar 2014

United Therapeutics' Remodulin Injection gets approval in Japan for PAH treatment

United Therapeutics Corporation today announced that Japan's Ministry of Health, Labour and Welfare has granted approval for Remodulin (treprostinil) Injection for the treatment of pulmonary arterial hypertension (PAH) by subcutaneous and intravenous administration.

26 Mar 2014

e-Therapeutics obtains MHRA approval to recommence recruitment for ETS2101 phase Ia trial

e-Therapeutics plc announces today that it has received approval from MHRA to recommence recruitment of new patients into its ETS2101 phase Ia solid tumours trial being conducted at three centres in the UK.

26 Mar 2014

BIND Therapeutics reports revenue of $2.1 million for fourth quarter 2013

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today reported financial results for the fourth quarter and year-ended December 31, 2013.

25 Mar 2014

Genable Technologies, Spark Therapeutics to advance novel therapy for rare form of retinitis pigmentosa

Spark Therapeutics and Genable Technologies announced today that they have entered into a collaboration agreement for Genable's lead therapeutic to treat rhodopsin-linked autosomal dominant retinitis pigmentosa (RHO adRP), GT038.

25 Mar 2014

Radiation therapy fights cancer in more ways than one

Radiation therapy fights cancer in more ways than one. Not only does it force cancer cells to self-destruct, but several studies demonstrate that it also activates the immune system to attack tumor cells.

25 Mar 2014

New technology gives tool to examine membrane proteins in natural environment of human cell

Scientists have a better way to study human proteins - large molecules that are part of every cell in the body - thanks to a new technology developed by University of Toronto researchers.

25 Mar 2014

Diabetes drug reduces amyloid-beta peptides, improves memory in experimental AD models

Researchers from Boston University School of Medicine have found that the diabetic drug, pramlintide, reduces amyloid-beta peptides, a major component of Alzheimer's disease (AD) in the brain and improves learning and memory in two experimental AD models.

25 Mar 2014

Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.

24 Mar 2014

Antisense Therapeutics enrolls acromegalic patients in ATL1103 Phase II trial

Antisense Therapeutics Limited is pleased to report that 24 acromegalic patients have been successfully enrolled and randomized to one of the two treatment regimens of dosing in the Phase II trial of ATL1103 for the growth disorder, acromegaly. This satisfies the necessary patient numbers proposed for the trial.

24 Mar 2014

NIH awards $28M grant to establish new center for excellence to find treatment for Ebola virus

The National Institutes of Health has awarded a five-year, $28 million grant to establish a new center for excellence to find an antibody "cocktail" to fight two types of viruses that cause severe hemorrhagic fever, including the deadly Ebola virus. The project involves researchers from 15 institutions, including Kartik Chandran, Ph.D., and Jonathan Lai, Ph.D., at Albert Einstein College of Medicine of Yeshiva University. Einstein will receive approximately $4 million of the total grant.

21 Mar 2014

Researchers uncover new connection between allergy and cancer

While many are stocking up on allergy medicine in preparation for spring, a new study from researchers at Virginia Commonwealth University Massey Cancer Center has uncovered a new connection between allergy and cancer that could potentially lead to therapies involving common antihistamines.

20 Mar 2014

Renal mass biopsy rates increasing in kidney cancer

Rates of renal mass biopsy have been historically low in patients with kidney cancer, but are steadily rising, shows an analysis of Medicare data.

19 Mar 2014

Horizon Pharma secures $250 million in acquisition financing from Deerfield Management

Deerfield Management Company announced today that it has provided up to $250 million in acquisition financing to Horizon Pharma, Inc. for the acquisition of Vidara Therapeutics International Ltd.

19 Mar 2014

Novan Therapeutics reports positive results from SB204 Phase 2 study for treatment of acne vulgaris

Novan Therapeutics, a specialty pharmaceutical company focused on advancing nitric oxide therapies for a number of diseases, announced today positive Phase 2 study results of its topical SB204 drug candidate for the treatment of acne vulgaris.

19 Mar 2014

Scientist receives SFI Saint Patrick's Day Science Medal from the prime minister of Ireland

Enda Kenny, the prime minister of Ireland, presented Garret A. FitzGerald, MD, FRS, director of the Institute for Translational Medicine and Therapeutics and chair of the Department of Pharmacology, Perelman School of Medicine, University of Pennsylvania, with the inaugural St. Patrick's Day Science Medal at an Science Foundation Ireland (SFI)-hosted event in Washington D.C. last week.

19 Mar 2014

Chemical engineers design way to manufacture peptides in mere hours

Small protein fragments, also called peptides, are promising as drugs because they can be designed for very specific functions inside living cells. Insulin and the HIV drug Fuzeon are some of the earliest successful examples, and peptide drugs are expected to become a $25 billion market by 2018.

19 Mar 2014

Therapeutics News and Research

SAGE Therapeutics doses first patient in SAGE-547 Phase 1/2 trial for treatment of SRSE

Echo Therapeutics reports net loss of $3.9M in fourth quarter 2013

Research may lead the way toward new treatments for proliferative retinopathies

Mast Therapeutics reports net loss of $5.7 million for fourth quarter 2013

United Therapeutics' Remodulin Injection gets approval in Japan for PAH treatment

e-Therapeutics obtains MHRA approval to recommence recruitment for ETS2101 phase Ia trial

BIND Therapeutics reports revenue of $2.1 million for fourth quarter 2013

Genable Technologies, Spark Therapeutics to advance novel therapy for rare form of retinitis pigmentosa

Radiation therapy fights cancer in more ways than one

New technology gives tool to examine membrane proteins in natural environment of human cell

Diabetes drug reduces amyloid-beta peptides, improves memory in experimental AD models

Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

Antisense Therapeutics enrolls acromegalic patients in ATL1103 Phase II trial

NIH awards $28M grant to establish new center for excellence to find treatment for Ebola virus

Researchers uncover new connection between allergy and cancer

Renal mass biopsy rates increasing in kidney cancer

Horizon Pharma secures $250 million in acquisition financing from Deerfield Management

Novan Therapeutics reports positive results from SB204 Phase 2 study for treatment of acne vulgaris

Scientist receives SFI Saint Patrick's Day Science Medal from the prime minister of Ireland

Chemical engineers design way to manufacture peptides in mere hours

Industry Focus eBook - Cell biology (5th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News